DK3487851T3 - Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer - Google Patents

Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer Download PDF

Info

Publication number
DK3487851T3
DK3487851T3 DK17830463.0T DK17830463T DK3487851T3 DK 3487851 T3 DK3487851 T3 DK 3487851T3 DK 17830463 T DK17830463 T DK 17830463T DK 3487851 T3 DK3487851 T3 DK 3487851T3
Authority
DK
Denmark
Prior art keywords
inhibitors
aminopyridine derivatives
selective alk
alk
selective
Prior art date
Application number
DK17830463.0T
Other languages
Danish (da)
English (en)
Inventor
Luca Arista
Sreehari Babu
Rene Lattmann
Lv Liao
Dimitrios Lizos
Rita Ramos
Nikolaus Johannes Stiefl
Thomas Ullrich
Peggy Usselmann
Xiaoyang Wang
Liladhar Murlidhar Waykole
Sven Weiler
Yubo Zhang
Jialiang Li
Jianwei Bian
Kai Cui
Michael Patrick Dillon
Yizong Zhou
Tingying Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3487851T3 publication Critical patent/DK3487851T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK17830463.0T 2016-07-20 2017-07-18 Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer DK3487851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
DK3487851T3 true DK3487851T3 (da) 2021-12-20

Family

ID=60991950

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17830463.0T DK3487851T3 (da) 2016-07-20 2017-07-18 Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer
DK21202619.9T DK3971177T3 (da) 2016-07-20 2017-07-18 Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21202619.9T DK3971177T3 (da) 2016-07-20 2017-07-18 Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer

Country Status (25)

Country Link
US (3) US10710980B2 (OSRAM)
EP (3) EP3971177B1 (OSRAM)
JP (4) JP7030776B2 (OSRAM)
KR (7) KR102359707B1 (OSRAM)
CN (2) CN109641871B (OSRAM)
AR (1) AR109108A1 (OSRAM)
AU (5) AU2017298187B2 (OSRAM)
CY (1) CY1124967T1 (OSRAM)
DK (2) DK3487851T3 (OSRAM)
EA (2) EA202190285A1 (OSRAM)
ES (2) ES2984746T3 (OSRAM)
FI (1) FI3971177T3 (OSRAM)
HR (2) HRP20211868T1 (OSRAM)
HU (2) HUE067992T2 (OSRAM)
LT (2) LT3971177T (OSRAM)
MX (2) MX388518B (OSRAM)
PL (2) PL3487851T3 (OSRAM)
PT (2) PT3971177T (OSRAM)
RS (2) RS66041B1 (OSRAM)
RU (1) RU2747318C2 (OSRAM)
SI (2) SI3487851T1 (OSRAM)
SM (2) SMT202100723T1 (OSRAM)
TW (5) TWI755255B (OSRAM)
UY (1) UY37331A (OSRAM)
WO (1) WO2018014829A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3971177T (lt) * 2016-07-20 2024-08-26 Novartis Ag Aminopiridino dariniai ir jų panaudojimas kaip selektyvių alk-2 inhibitorių
KR20220107213A (ko) * 2019-11-22 2022-08-02 인사이트 코포레이션 Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
DE69332779T2 (de) 1992-11-17 2003-10-23 Ludwig Institut For Cancer Research, Padington Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20040265909A1 (en) 2003-04-11 2004-12-30 Jeff Blaney Compound libraries and methods for drug discovery
AU2005247699A1 (en) 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
AU2006234627C1 (en) 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
US20080021024A1 (en) 2006-06-29 2008-01-24 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
JP2010502220A (ja) 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
JP2010503383A (ja) 2006-09-12 2010-02-04 ザ ジェネラル ホスピタル コーポレイション 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
CA2807343C (en) 2010-08-20 2018-05-22 Wyeth Llc Designer osteogenic proteins
BR112013013837A2 (pt) 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
BR112013029640A2 (pt) 2011-05-23 2017-06-13 Merck Patent Gmbh derivados de piridina e pirazina
KR102527562B1 (ko) 2011-09-09 2023-05-03 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
ES2660051T3 (es) * 2012-09-28 2018-03-20 Vanderbilt University Compuestos heterocíclicos condensados como inhibidores selectivos de BMP
WO2014138088A1 (en) * 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
US10202356B2 (en) * 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
HUE044683T2 (hu) 2013-10-21 2019-11-28 Merck Patent Gmbh Heteroaril vegyületek mint BTK inhibitorok és alkalmazásuk
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
MY199607A (en) 2015-08-31 2023-11-09 Dong A Socio Holdings Co Ltd Heteroaryl compounds and their use as therapeutic drugs
JP7030775B2 (ja) 2016-07-20 2022-03-07 キャベンディッシュ・キネティックス・インコーポレイテッド Ｄｖｃを用いてアンテナを調整する方法
LT3971177T (lt) * 2016-07-20 2024-08-26 Novartis Ag Aminopiridino dariniai ir jų panaudojimas kaip selektyvių alk-2 inhibitorių
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
EA037520B1 (ru) 2021-04-07
RS66041B1 (sr) 2024-11-29
TWI851226B (zh) 2024-08-01
KR20230117248A (ko) 2023-08-07
TWI755255B (zh) 2022-02-11
ES2902521T3 (es) 2022-03-28
PL3487851T3 (pl) 2022-04-11
AU2023200265A1 (en) 2023-02-16
US10710980B2 (en) 2020-07-14
EP3487851B1 (en) 2021-10-20
TW202509017A (zh) 2025-03-01
KR20220021023A (ko) 2022-02-21
EP3971177A1 (en) 2022-03-23
MX2021014852A (es) 2022-01-18
KR102719881B1 (ko) 2024-10-23
KR20210094138A (ko) 2021-07-28
RU2747318C2 (ru) 2021-05-04
TWI806385B (zh) 2023-06-21
EP3487851A1 (en) 2019-05-29
CN114014844B (zh) 2024-10-01
EP3487851A4 (en) 2019-12-25
HUE057328T2 (hu) 2022-05-28
KR102281550B1 (ko) 2021-07-27
TW202134228A (zh) 2021-09-16
RU2021111037A3 (OSRAM) 2022-02-10
PT3971177T (pt) 2024-07-30
TWI712598B (zh) 2020-12-11
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
CN114014844A (zh) 2022-02-08
US20190161474A1 (en) 2019-05-30
MX2019000837A (es) 2019-07-04
AU2019246857A1 (en) 2019-10-31
JP7030776B2 (ja) 2022-03-07
KR102667331B1 (ko) 2024-05-21
RS62819B1 (sr) 2022-02-28
KR20240155367A (ko) 2024-10-28
EP3971177B1 (en) 2024-06-26
UY37331A (es) 2018-02-28
US20200299265A1 (en) 2020-09-24
RU2019104609A (ru) 2020-08-20
HRP20241015T1 (hr) 2024-11-08
US12466808B2 (en) 2025-11-11
CA3030332A1 (en) 2018-01-25
JP2019521167A (ja) 2019-07-25
EA202190285A1 (ru) 2021-08-31
CN109641871A (zh) 2019-04-16
TW201805277A (zh) 2018-02-16
AU2023200265B2 (en) 2024-08-15
RU2021111037A (ru) 2021-05-13
AU2021201424A1 (en) 2021-03-25
TW202220969A (zh) 2022-06-01
AU2021201424B2 (en) 2022-10-20
AU2024205058A1 (en) 2024-08-15
SI3971177T1 (sl) 2024-10-30
LT3971177T (lt) 2024-08-26
JP2022078137A (ja) 2022-05-24
KR102359707B1 (ko) 2022-02-09
DK3971177T3 (da) 2024-07-15
MX388518B (es) 2025-03-19
RU2019104609A3 (OSRAM) 2020-09-30
KR102559539B1 (ko) 2023-07-26
ES2984746T3 (es) 2024-10-30
JP2023089012A (ja) 2023-06-27
PT3487851T (pt) 2022-01-07
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10
CY1124967T1 (el) 2023-01-05
EP4442317A3 (en) 2025-01-01
LT3487851T (lt) 2021-12-27
JP7253086B2 (ja) 2023-04-05
US10947218B2 (en) 2021-03-16
AU2017298187A1 (en) 2018-12-20
CN109641871B (zh) 2021-10-22
TW202336011A (zh) 2023-09-16
JP2025032086A (ja) 2025-03-11
KR20220143770A (ko) 2022-10-25
JP7584553B2 (ja) 2024-11-15
WO2018014829A1 (en) 2018-01-25
KR20240074904A (ko) 2024-05-28
EA201990343A1 (ru) 2019-06-28
KR102454129B1 (ko) 2022-10-14
PL3971177T3 (pl) 2024-10-28
BR112019000941A2 (pt) 2019-04-30
FI3971177T3 (fi) 2024-07-30
US20210155606A1 (en) 2021-05-27
HRP20211868T1 (hr) 2022-03-04
KR20190026917A (ko) 2019-03-13
EP4442317A2 (en) 2024-10-09
HUE067992T2 (hu) 2024-12-28
SMT202400335T1 (it) 2024-09-16
AR109108A1 (es) 2018-10-31
AU2019246857B2 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3328849T5 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3331894T3 (da) Nicotinamidmononukleotidderivater og anvendelser deraf
DK3307707T3 (da) Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK2970187T3 (da) 4-amino-6-(heterocycliske)picolinater og deres anvendelse som herbicider
DK3786160T3 (da) Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
DK3559000T3 (da) Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
DK3310784T3 (da) Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
EP3426242A4 (en) ICARITINE AND ICARITINE DERIVATIVES
DK3487851T3 (da) Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer
DK3347353T3 (da) Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler
DK3214079T3 (da) Seks-leddede benzodiazepinderivater som dpp-4-inhibitorer og hvordan de bruges
DK3347356T3 (da) Tricyclic forbundet pyridin-2-one-derivater og deres anvendelse som brd4-hæmmere
DK3398598T3 (da) Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
DK3724196T3 (da) Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
DK3455216T3 (da) Pyridinylderivater, farmaceutiske sammensætninger og anvendelser deraf som aoc3-inhibitorer
DK3277682T3 (da) 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere
DK3362450T3 (da) N1- og N7-substituerede sibirilin-derivater og anvendelse deraf som inhibitorer af cellulær nekroptose
DK3555048T3 (da) Nye picolinsyrederivater og deres anvendelse som mellemprodukter
DK3551634T3 (da) Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere